Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D N Rose

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Public Health Reports (Washington, D.C. : 1974)|January 1, 1984
The underreporting of disease and physicians' knowledge of reporting requirementsP M Konowitz, G A Petrossian, D N Rose
JAMA|November 21, 1986
The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactorsD N Rose, C B Schechter, A L Silver
The American Journal of Medicine|February 1, 1993
Influenza and pneumococcal vaccination of HIV-infected patients: a policy analysisD N Rose, C B Schechter, H S Sacks
Journal of General Internal Medicine|November 1, 1992
Preventive medicine for HIV-infected patients: an analysis of isoniazid prophylaxis for tuberculin reactors and for anergic patientsD N Rose, C B Schechter, H S Sacks
Journal of General Internal Medicine|November 1, 1995
Interpretation of the tuberculin skin testD N Rose, C B Schechter, J J Adler
The Mount Sinai Journal of Medicine, New York|April 1, 1985
Tuberculosis chemoprophylaxis for diabetics: are the benefits of isoniazid worth the risk?D N Rose, A L Silver, C B Schechter
AIDS (London, England)|August 28, 1999
Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effectiveJ C Bell, D N Rose, H S Sacks
JAMA|December 28, 1984
Should the risk of acquired immunodeficiency syndrome deter hepatitis B vaccination? A decision analysisH S Sacks, D N Rose, T C Chalmers
JAMA|August 21, 1987
Discounting, isoniazid, and tuberculosisD N Rose, C B Schechter, A L Silver
Ear and Hearing|August 1, 1987
Hearing loss screening in the neonatal intensive care unit: auditory brain stem response versus Crib-O-Gram; a cost-effectiveness analysisD A Prager, D A Stone, D N Rose
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Public Health Reports (Washington, D.C. : 1974)|January 1, 1984
The underreporting of disease and physicians' knowledge of reporting requirementsP M Konowitz, G A Petrossian, D N Rose
JAMA|November 21, 1986
The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactorsD N Rose, C B Schechter, A L Silver
The American Journal of Medicine|February 1, 1993
Influenza and pneumococcal vaccination of HIV-infected patients: a policy analysisD N Rose, C B Schechter, H S Sacks
Journal of General Internal Medicine|November 1, 1992
Preventive medicine for HIV-infected patients: an analysis of isoniazid prophylaxis for tuberculin reactors and for anergic patientsD N Rose, C B Schechter, H S Sacks
Journal of General Internal Medicine|November 1, 1995
Interpretation of the tuberculin skin testD N Rose, C B Schechter, J J Adler
The Mount Sinai Journal of Medicine, New York|April 1, 1985
Tuberculosis chemoprophylaxis for diabetics: are the benefits of isoniazid worth the risk?D N Rose, A L Silver, C B Schechter
AIDS (London, England)|August 28, 1999
Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effectiveJ C Bell, D N Rose, H S Sacks
JAMA|December 28, 1984
Should the risk of acquired immunodeficiency syndrome deter hepatitis B vaccination? A decision analysisH S Sacks, D N Rose, T C Chalmers
JAMA|August 21, 1987
Discounting, isoniazid, and tuberculosisD N Rose, C B Schechter, A L Silver
Ear and Hearing|August 1, 1987
Hearing loss screening in the neonatal intensive care unit: auditory brain stem response versus Crib-O-Gram; a cost-effectiveness analysisD A Prager, D A Stone, D N Rose
Pageof 5